"CAMouse," which CAMAB has developed its own human antibody mouse strains (CAMouseHG) and human single-domain antibody mouse strains (CAMouseH), has entered into a deep cooperation agreement with Cyagen on the whole human antibody mouse platform. In addition, Cyagen has a mature gene and cell therapy drug development platform and will act as the CRO service provider of this mouse platform, providing cell therapy services such as CAR series in vitro and in vivo functional validation. Both parties will complement each other to promote the development and clinical translation of cell therapy drugs and antibody drugs.

The development of antibody drugs has gone through different stages mouse-derived antibodies, chimeric antibodies, humanized antibodies, and fully human antibodies, with fully human antibodies being the mainstream of antibody-drug development and fully human antibody mouse strains being the source of fully human antibody drug development. In addition, more than 2/3 of the approved human antibody drugs are derived from whole human antibody mouse strains.

CAMouse is currently the only fully human antibody mouse strain that has been independently bred for fully human antibody drug development in China. It expresses fully human immunoglobulin light chain gene and fully human immunoglobulin heavy chain gene while mouse endogenous IgH and IgK are inactivated. Based on Kimberly's breakthrough genetic modification technology and antibody time-shift expression technology, CAMouse can rapidly and efficiently produce fully human antibodies with good diversity, high affinity, and good druggability. Currently, CAMouse has been applied to dozens of antibody-drug discovery projects in many companies at home and abroad.

Strategic Collaboration on a Fully Human Antibody Mouse Platform

Immunotherapy is one of the most promising directions in oncology and is considered the most promising treatment for "curing" cancer. Among the numerous immune cell therapies, the most advanced and mature is CAR-T therapy, which has 7 products approved by FDA and 2 products listed in China. Cell therapy is entering a golden track of rapid development as a breakthrough treatment technology. Based on years of research experience in the field of tumor immunity, Cyagen provides CAR-T and other cell therapy researchers with a full range of services from CAR virus preparation, immune cell preparation, cell model and animal model construction to in vivo/in vitro efficacy evaluation, providing comprehensive support for CAR-T and cell therapy R&D.

Cyagen Bio Cell Therapy CRO Platform

The strong combination of the Cyagen cell therapy platform and CAMAB's whole human antibody transgenic mouse platform will provide more comprehensive and efficient cell therapy CRO services for research and pharmaceutical companies and comprehensively improve the speed and core competitiveness of innovative antibody-drug product development.

About Cyagen

Founded in 2006, Cyagen is an innovative CRO that uses data, algorithms, and models to accelerate the development of new drugs. Based on animal models and the deep exploration of artificial intelligence, Cyagen has been at the forefront of the industry in the field of gene editing animal models, from the animal model repository, model customization, breeding, and sterile mouse technology service to phenotype function validation, to meet customers' needs for animal models in basic research and new drug development comprehensively and intelligently.

At the same time, Cyagen has been enriching its product lines, strengthening its data and model advantages, and prospectively laying out the gene therapy and cell therapy fields, combining target prediction and validation platform, viral vector development platform, evaluation model construction platform, and efficacy evaluation platform to take off again in the track conversion. Currently, Cyagen has more than 900 employees and a total scale of over 40,000 square meters, with wholly-owned subsidiaries in Guangzhou, and Suzhou, offices in Chengdu, Beijing, Shanghai, Wuhan, and Changsha, and subsidiaries in Santa Clara, the USA, and Tokyo, Japan. Cyagen has established extensive cooperation with scientists and enterprises in more than 100 countries and regions around the world, and its products and technologies have been directly applied to the research projects of more than 6300 published academic papers, including "CNS" (Cell, Nature， and Science).

With the corporate vision of creating unlimited possibilities for biotechnology, Cyagen is willing to develop a bright future with global pharmaceutical R&D personnel!